Pfizer & BioNTech sign agreement with Biovac Institute in South Africa

Both companies expect that Biovac’s Cape Town facility will be incorporated in their global vaccine supply chain by the end of 2021, while technical processes and on-site equipment activities will start immediately, the statement added.

Pfizer and BioNTech have signed an agreement with South Africa’s Biovac Institute to produce the COVID-19 vaccine in South Africa for the African Union, Pfizer in a statement said today.

Both companies expect that Biovac’s Cape Town facility will be incorporated in their global vaccine supply chain by the end of 2021, while technical processes and on-site equipment activities will start immediately, the statement added.

advt

Pfizer Chairman and CEO Albert Bourla said that our latest collaboration with Biovac is a shining example of the tireless work being done, in this instance to benefit Africa. He promised to continue efforts to expand the vaccine supply chain in other regions, including Latin America.

At full operational capacity, the annual production will exceed 100 million finished doses, which will be distributed within the 55 member states of the African Union, the statement said.

To date, Pfizer and BioNTech have shipped more than 1 billion COVID-19 vaccine doses to more than 100 countries or territories in every region of the world.

Tags
advt

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button